CTLA-4-话题@MedSci

#CTLA-4#

43篇内容 | 2923人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2240501, encodeId=7d2f2240501bd, content=<a href='/topic/show?id=19d412195921' target=_blank style='color:#2F92EE;'>#马普替林#</a>通过靶向E3泛素连接酶（SPOP）抑制PD-L1表达，从而发挥抗肿瘤作用（图4D-F）。此外，研究者通过体内实验发现，马普替林与抗细胞毒性T淋巴细胞相关抗原4（<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>）药物具有协同作用，能够发挥更好抗肿瘤效果（图4G-H）。本研究揭示了马普替林在抗肿瘤方面的潜在应用价值，为<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>和<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a>的临床治疗提供了新的策略。<a href='/topic/show?id=9efb80281aa' target=_blank style='color:#2F92EE;'>#老药新用#</a><a href='/topic/show?id=6c6b5559ea5' target=_blank style='color:#2F92EE;'>#抗精神病药物#</a>, objectTitle=Adv Sci：四环类抗抑郁药物马普替林靶向E3泛素连接酶SPOP发挥抗肿瘤作用, objectType=article, longId=853692, objectId=720a853692b2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241101/8d5771f423b84325b7e8fed3b5d8d20a-Rxpba1RaOY8H.jpg, objectUrl=/article/show_article.do?id=720a853692b2, replyNumber=0, likeNumber=38, createdTime=2024-12-03, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=720a853692b2, moduleTitle=Adv Sci：四环类抗抑郁药物马普替林靶向E3泛素连接酶SPOP发挥抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=720a853692b2)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2190592, encodeId=118c21905923e, content=<a href='/topic/show?id=7cfe2903248' target=_blank style='color:#2F92EE;'>#免疫抑制#</a> <a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=读书报告 | Treg细胞的CTLA-4非依赖性免疫抑制机制干扰CTLA-4抗体抗肿瘤疗效, objectType=article, longId=815293, objectId=0a66815293a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=0a66815293a4, replyNumber=0, likeNumber=150, createdTime=2024-03-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0a66815293a4, moduleTitle=读书报告 | Treg细胞的CTLA-4非依赖性免疫抑制机制干扰CTLA-4抗体抗肿瘤疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a66815293a4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2118378, encodeId=907621183e82c, content=靶向抑制性协同受体<a href='/topic/show?id=234613893a4' target=_blank style='color:#2F92EE;'>#PD-1#</a>和<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>的<a href='/topic/show?id=ca8e1054893b' target=_blank style='color:#2F92EE;'>#检查点免疫疗法#</a>彻底改变了<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗，而<a href='/topic/show?id=67c61046e460' target=_blank style='color:#2F92EE;'>#LAG-3#</a>作为新一**现的抑制性检查点，有望成为<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>治疗中极具前景的<a href='/topic/show?id=07a69996557' target=_blank style='color:#2F92EE;'>#靶点#</a>。最近比较火的是PD-L1/LAG3<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>，一举两得, objectTitle=带你了解免疫检查点靶点： LAG-3, objectType=article, longId=754269, objectId=b2aae5426966, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230101/1672578147334_8252897.jpg, objectUrl=/article/show_article.do?id=b2aae5426966, replyNumber=0, likeNumber=218, createdTime=2023-03-09, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b2aae5426966, moduleTitle=带你了解免疫检查点靶点： LAG-3, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2aae5426966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461896, encodeId=571814618967f, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, objectType=article, longId=737420, objectId=555de3742013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555de3742013, replyNumber=0, likeNumber=123, createdTime=2022-09-01, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555de3742013, moduleTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555de3742013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461895, encodeId=9113146189590, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=潜在同类最佳安全性，抗CTLA-4安全抗体ADG126相关数据将在ASCO公布, objectType=article, longId=727918, objectId=c0f6e2791867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f6e2791867, replyNumber=0, likeNumber=0, createdTime=2022-05-28, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f6e2791867, moduleTitle=潜在同类最佳安全性，抗CTLA-4安全抗体ADG126相关数据将在ASCO公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0f6e2791867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461894, encodeId=c5021461894fb, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡, objectType=article, longId=300374, objectId=81c23003e459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81c23003e459, replyNumber=0, likeNumber=103, createdTime=2022-03-11, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81c23003e459, moduleTitle=条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81c23003e459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461893, encodeId=ac80146189385, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, objectType=article, longId=292558, objectId=2c632925589c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c632925589c, replyNumber=0, likeNumber=105, createdTime=2021-12-24, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c632925589c, moduleTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c632925589c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461892, encodeId=e7b4146189232, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=221346, objectId=ab662213469b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab662213469b, replyNumber=0, likeNumber=86, createdTime=2021-12-02, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab662213469b, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab662213469b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461891, encodeId=276b146189120, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=JCEM：PD-1和CTLA-4阻断剂会增加甲状腺功能障碍的风险, objectType=article, longId=220894, objectId=3cc7220894b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cc7220894b1, replyNumber=0, likeNumber=96, createdTime=2021-11-25, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cc7220894b1, moduleTitle=JCEM：PD-1和CTLA-4阻断剂会增加甲状腺功能障碍的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cc7220894b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461890, encodeId=2cef14618907b, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Nat Med：肠道微生物组特征与CTLA-4和PD-1联合阻断治疗毒性相关, objectType=article, longId=214203, objectId=638f214203a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=638f214203a8, replyNumber=0, likeNumber=116, createdTime=2021-07-15, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=638f214203a8, moduleTitle=Nat Med：肠道微生物组特征与CTLA-4和PD-1联合阻断治疗毒性相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=638f214203a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461889, encodeId=b5cf146188962, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定, objectType=article, longId=207633, objectId=bf5620e63327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf5620e63327, replyNumber=0, likeNumber=103, createdTime=2021-02-28, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf5620e63327, moduleTitle=全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf5620e63327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461888, encodeId=3b8914618880a, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, objectType=article, longId=202749, objectId=c7e3202e494d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7e3202e494d, replyNumber=0, likeNumber=88, createdTime=2020-11-03, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7e3202e494d, moduleTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7e3202e494d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461887, encodeId=d4b1146188e24, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Nat Commun：短链脂肪酸可能会减弱CTLA-4类肿瘤免疫治疗效果, objectType=article, longId=202089, objectId=ecdb202089cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecdb202089cf, replyNumber=0, likeNumber=93, createdTime=2020-10-15, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecdb202089cf, moduleTitle=Nat Commun：短链脂肪酸可能会减弱CTLA-4类肿瘤免疫治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecdb202089cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461886, encodeId=bb40146188626, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定, objectType=article, longId=200285, objectId=7fde2002858b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fde2002858b, replyNumber=0, likeNumber=103, createdTime=2020-09-06, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fde2002858b, moduleTitle=康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fde2002858b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461885, encodeId=6447146188510, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定, objectType=article, longId=199753, objectId=c938199e53cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c938199e53cd, replyNumber=0, likeNumber=0, createdTime=2020-08-22, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c938199e53cd, moduleTitle=康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c938199e53cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461884, encodeId=f25d14618845b, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=73, createdTime=2020-06-10, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461883, encodeId=d515146188323, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=93, createdTime=2020-05-18, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461882, encodeId=4739146188263, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, objectType=article, longId=194237, objectId=1da819423ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da819423ef7, replyNumber=0, likeNumber=0, createdTime=2020-05-17, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da819423ef7, moduleTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da819423ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461881, encodeId=50cf146188138, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=JAMA Oncol：PD-L1及CTLA-4双重抑制或可改善晚期结肠癌患者生存期, objectType=article, longId=194071, objectId=0c321940e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c321940e154, replyNumber=0, likeNumber=106, createdTime=2020-05-14, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c321940e154, moduleTitle=JAMA Oncol：PD-L1及CTLA-4双重抑制或可改善晚期结肠癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c321940e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461880, encodeId=04351461880d8, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, objectType=article, longId=193387, objectId=c66b19338e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66b19338e62, replyNumber=0, likeNumber=92, createdTime=2020-05-04, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66b19338e62, moduleTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c66b19338e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CTLA-4

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

全文收起 #马普替林#通过靶向E3泛素连接酶（SPOP）抑制PD-L1表达，从而发挥抗肿瘤作用（图4D-F）。此外，研究者通过体内实验发现，马普替林与抗细胞毒性T淋巴细胞相关抗原4（#CTLA-4#）药物具有协同作用，能够发挥更好抗肿瘤效果（图4G-H）。本研究揭示了马普替林在抗肿瘤方面的潜在应用价值，为#结直肠癌#和#肺癌#的临床治疗提供了新的策略。#老药新用##抗精神病药物#

Adv Sci：四环类抗抑郁药物马普替林靶向E3泛素连接酶SPOP发挥抗肿瘤作用

2024-12-03发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#免疫抑制# #CTLA-4#

读书报告 | Treg细胞的CTLA-4非依赖性免疫抑制机制干扰CTLA-4抗体抗肿瘤疗效

2024-03-02发表于上海

showtest (审核中...)

前往app查看评论内容

靶向抑制性协同受体#PD-1#和#CTLA-4#的#检查点免疫疗法#彻底改变了#癌症#治疗，而#LAG-3#作为新一**现的抑制性检查点，有望成为#肿瘤#治疗中极具前景的#靶点#。最近比较火的是PD-L1/LAG3#双特异性抗体#，一举两得

带你了解免疫检查点靶点： LAG-3

2023-03-09发表于上海

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准

2022-09-01

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

潜在同类最佳安全性，抗CTLA-4安全抗体ADG126相关数据将在ASCO公布

2022-05-28

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡

2022-03-11

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著

2021-12-24

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2021-12-02

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

JCEM：PD-1和CTLA-4阻断剂会增加甲状腺功能障碍的风险

2021-11-25

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Nat Med：肠道微生物组特征与CTLA-4和PD-1联合阻断治疗毒性相关

2021-07-15

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定

2021-02-28

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法

2020-11-03

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Nat Commun：短链脂肪酸可能会减弱CTLA-4类肿瘤免疫治疗效果

2020-10-15

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定

2020-09-06

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定

2020-08-22

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-06-10

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2020-05-18

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％

2020-05-17

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

JAMA Oncol：PD-L1及CTLA-4双重抑制或可改善晚期结肠癌患者生存期

2020-05-14

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果

2020-05-04

科室
- - 订阅+
  - 更多科室
工具
服务